CTIS2023-507732-20-00进行中（未招募）1 期
A randomized double blind, multicenter trial to assess time-interval between cytoreductive surgery and adjuvant chemotherapy after administration of local anesthetic intraperitoneally/perioperatively in advanced epithelial ovarian cancer - IPLA-OVCA
Karolinska University Hospital0 个研究点目标入组 220 人开始时间: 2023年8月18日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 220
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
入选标准
- •Women > 18 years, ASA I-III, Scheduled for upfront cytoreductive surgery for stage III or IV epithelial ovarian cancer, Signed written informed consent
排除标准
- •Contraindication to epidural anesthesia, Allergy to any component drugs used during epidural or intraperitoneal anesthesia (Ropivacaine, Sufentanil), Uncontrolled renal, liver, heart failure or ischemic heart disease, Speech, language or cognitive difficulties, Women in whom cytoreductive surgery is not attempted at time of upfront laparotomy due to extent of disease
研究者
相似试验
进行中（未招募）
1 期
Can local anesthetics given inside the abdominal cavity during and up to 72 h after surgery reduce the time to start of chemotherapy after sugeryEUCTR2019-003299-38-SEKarolinska University Hospital220
尚未招募
2 期
BeatNF2 trialJPRN-jRCT2080224914Kiyoshi Saito60
进行中（未招募）
1 期
A study to investigate the safety and efficacy of a six month oral treatment with a twice daily dose of BAY 1142524 in comparison to placebo in patients with reduced left-ventricular ejection fraction after acute myocardial infarction.EUCTR2016-002167-33-CZBayer AG185
进行中（未招募）
1 期
A study to investigate the safety and efficacy of a six month oral treatment with a twice daily dose of BAY 1142524 in comparison to placebo in patients with reduced left-ventricular ejection fraction after acute myocardial infarctioeft-ventricular dysfunction after acute myocardial infarctionEUCTR2016-002167-33-ESBayer AG140
进行中（未招募）
1 期
A study to investigate the safety and efficacy of a six month oral treatment with a twice daily dose of BAY 1142524 in comparison to placebo in patients with reduced left-ventricular ejection fraction after acute myocardial infarctioEUCTR2016-002167-33-DEBayer AG185